biologics 結果共7筆

Discover how AltruBio’s CEO, Judy Chou, champions the ＂Created In Taiwan＂ initiative for new drug development at the Bio Taiwan Committee meeting, aiming to make Taiwan a global hub for biotech innovation.

Vice Presidential candidate Hsiao Bi-khim of the Democratic Progressive Party (DPP) vows to review and reflect on corruption allegations within the DPP government. This comes after her opponent, Kuomintang’s (KMT) Jaw Shaw-kong, accused the DPP of corruption during a policy presentation. Jaw raised concerns about the DPP obstructing Terry Gou’s acquisition of Pfizer-BioNTech vaccines and questioned the increase in the market value of Medigen Vaccine Biologics Corp. He advocated for the reinstatement of the Special Investigation Division to tackle corruption. Hsiao acknowledges mistakes within the party and emphasizes the need for self-review. She highlights the DPP’s commitment to reform and progressive policies, citing examples of marriage equality and energy transformation. Hsiao compares the government to a team in an international competition, emphasizing the importance of guidance and support for a unified nation.

The Taiwan FactCheck Center has clarified that MVC’s quadrivalent influenza vaccine is produced by the reputable South Korean pharmaceutical firm GC Biopharma, which has WHO qualification and is marketed in multiple countries. Additionally, the FactCheck Center noted that MVC’s method of vaccine production is not unprecedented, as other domestic manufacturers have also imported foreign vaccine stock solutions for local assembly.

南韓三星生物製劑（Samsung Biologics）日前與美國藥廠莫德納簽約，獲得新冠疫苗的代理生產授權，於今年8月完成試產後，投入第3季正式生產。南韓官方今（26）日對外透露，由三星生產的首批243萬5000劑莫德納即將於本週出貨，有望將疫苗留在國內使用。

日本研發COVID-19疫苗的製藥公司「KM生物」（KM Biologics）今天表示，研發疫苗計畫提前，最快明年春天提出藥事承認申請，明年底可以開始提供疫苗。

南韓三星生物製劑（Samsung Biologics）傳出已於今年8月完成莫德納疫苗試生產，並按照原先規劃，自第3季開始正式在南韓國內生產莫德納疫苗，預計將把產出的劑量提供給除了美國以外的國際市場。

中國康希諾生物（CanSino Biologics）今天表示，他們所研製的COVID-19疫苗在匈牙利已獲准緊急使用，是匈牙利國內核准的第2款中國製疫苗。